# Targeting neuroinflammation in Alzheimer`s disease

 Andris OZOLS1,\*,Anna LIEPA2

*1Department of Pharmacology, Faculty of Medicine, Riga, University of Latvia,*

*2Institute of Neuroscience, University of Newcastle, Newcastle, United Kingdom*

*Corresponding author:*Andris OZOLS\*, *Department of Pharmacology, Faculty of Medicine, University of Latvia, 19 Raina Blvd, LV-1586, Riga, Latvia. E-mail:* *andris.ozols@lu.lv*

**Background:** ............................................................................................

**Objectives:** ...............................................................................................

**Methods:** ...................................................................................................

**Results:** .....................................................................................................

**Conclusions:** .............................................................................................

**Acknowledgments:** ...................................................................................

**Keywords:** .........................................................................................................

**References** ……………………………………………………………………

|  |  |
| --- | --- |
| I wish my abstract to be considered for the Young Scientists Poster Award | Yes/No |
| If “Yes”, I confirm that the presenting author under the age of 35 years | Yes/No |

**ABSTRACT BODY including Background, Objectives, Methods, Results, Conclusions with maximum 350 words in font size 12.**

##### **Short Guidelines for Preparation of Abstracts**

***Receptor and ion channel nomenclature should follow the official IUPHAR nomenclature, please see: http://www.guidetopharmacology.org***

* **Title:**  The title in bold, **Sentence case**, limited to 25 words, avoid abbreviations, font size 14.
* **Author(s) name(s):** full first name and **in uppercase family name** should be stated (font size 12).
* **Author’s affiliations**: mentioned below author names, numbered, if applicable (in *italics*, font size 10). Include the name of the department, institute/university, city and country.
* **Presenting/corresponding author's:** name and family name of presenting author should be marked **with Asterisk.** Full postal address and e-mail address of the corresponding author should be mentioned.

**Please include the following sections:**

* Background, Objectives, Methods, Results, Conclusions, Acknowledgments, Keywords, References (font size 12, Times New Roman, justified text)
* **Abstract Body** including Background, Objectives, Methods, Results, Conclusions should not exceed 350 words.
* Abstracts should be saved and uploaded in **.docx** (Word format).
* **Keywords:** up to 5 keywords, separated by commas.
* **References:** a maximum of four references, in the following manner: in the Abstract Body indicated with numbers in brackets: [1] or [1, 2].

Please give ***a full citation at the end of the ‘Abstract body’ in a separate paragraph ‘References’ (e.g. "1. Name N et al.: Journal name, Year, Volume, page numbers"***) in the following style:

**References**

1. Sha L., Linden DR, Farrugia G, Szursewski JH: **Hydrogen suffide selectively potentiates central preganglionic fast nicotinic synaptic input in mouse mesenteric ganglio.** *J Neurosci*, 2013; 31(31):12638-12646. doi:10.1523/JNEUROSCI.4429-12.2013
2. Pesaresi M, Soon-Shiong R, French L, Kaplan DR, Miller FD, Paus T: **Axon diameter and axonal transport: in vivo and in vitro effects of androgens.** *Neuroimage*, 2015; 115:191-202. doi:10.1016/j.neuroimage.2015.04.048